Thus, our screening strategy identified 3 compounds that reduce α-synuclein oligomer levels in mammalian neurons: rapamycin, which has previously demonstrated efficacy in an in vivo α-synuclein toxicity model of PD [62], losartan, which has previously shown neuroprotective potential but not via an α-synuclein-mediated mechanism [66, 67], and rifabutin, which has not yet been explored as a treatment for neurodegenerative diseases. Here, SNCA is linked to Parkinson disease.